MX2009011754A - Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. - Google Patents
Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.Info
- Publication number
- MX2009011754A MX2009011754A MX2009011754A MX2009011754A MX2009011754A MX 2009011754 A MX2009011754 A MX 2009011754A MX 2009011754 A MX2009011754 A MX 2009011754A MX 2009011754 A MX2009011754 A MX 2009011754A MX 2009011754 A MX2009011754 A MX 2009011754A
- Authority
- MX
- Mexico
- Prior art keywords
- diacylglycerol
- inhibitors
- enzyme
- acyltransferase type
- acyltransferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
La presente invención se refiere a compuestos de la fórmula (I): en donde Q, G1, G2 y G3, son como aquí se definen. También se describen composiciones farmacéuticas y métodos para el tratamiento de las enfermedades o padecimientos relacionados con la enzima DGAT-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91496307P | 2007-04-30 | 2007-04-30 | |
PCT/US2008/061951 WO2008134693A1 (en) | 2007-04-30 | 2008-04-30 | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009011754A true MX2009011754A (es) | 2009-12-01 |
Family
ID=39636871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011754A MX2009011754A (es) | 2007-04-30 | 2008-04-30 | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. |
Country Status (14)
Country | Link |
---|---|
US (2) | US8242139B2 (es) |
EP (2) | EP2142521A1 (es) |
JP (1) | JP2010526781A (es) |
KR (1) | KR20100017508A (es) |
CN (2) | CN101743234A (es) |
AU (1) | AU2008245461B2 (es) |
BR (1) | BRPI0810719A8 (es) |
CA (1) | CA2685529A1 (es) |
IL (1) | IL201753A0 (es) |
MX (1) | MX2009011754A (es) |
NZ (1) | NZ580660A (es) |
RU (1) | RU2497816C2 (es) |
WO (1) | WO2008134693A1 (es) |
ZA (1) | ZA200907613B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070087096A (ko) | 2004-12-14 | 2007-08-27 | 아스트라제네카 아베 | Dgat 억제제로서의 옥사디아졸 유도체 |
EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
ATE529405T1 (de) | 2006-03-31 | 2011-11-15 | Novartis Ag | (4-(4-ä6-(trifluoromethyl-pyridin-3-ylamino)-n- enthaltend-heteroarylü-phenyl)-cyclohexyl)- essigsäure-derivate und ihre pharmazeutische anwendungen |
CA2651710A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
WO2007138304A1 (en) * | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
CA2707660A1 (en) | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
EP3366686B9 (en) | 2009-03-20 | 2021-08-04 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof |
JP2012530122A (ja) * | 2009-06-19 | 2012-11-29 | アストラゼネカ アクチボラグ | Dgat1の阻害剤としてのピラジンカルボキシアミド |
EP2473513B1 (en) * | 2009-09-03 | 2019-06-05 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
IN2013MN00581A (es) * | 2010-09-03 | 2015-06-05 | Piramal Entpr Ltd | |
AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
US8617886B2 (en) | 2011-07-15 | 2013-12-31 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
CA2844982A1 (en) | 2011-08-15 | 2013-02-21 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
AU2014248742B2 (en) * | 2013-03-13 | 2018-04-05 | Abbvie Ireland Unlimited Company | Processes for the preparation of an apoptosis-inducing agent |
EP3191445B1 (en) * | 2014-09-09 | 2019-06-12 | Bristol-Myers Squibb Company | Cyclobutane containing carboxylic acid gpr120 modulators |
KR102615234B1 (ko) | 2018-09-21 | 2023-12-19 | 화이자 인코포레이티드 | Ccr6 억제제로서 유용한 n-치환된-디옥소시클로부테닐아미노-3-히드록시-피콜린아미드 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3418624B2 (ja) * | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | サイトカイン阻害活性を有する置換イミダゾール類 |
US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
CA2357874A1 (en) * | 1999-01-07 | 2000-07-13 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic compound |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
US7196106B2 (en) * | 2002-11-05 | 2007-03-27 | Merck & Co., Inc | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
TWI344961B (en) * | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
JP2007509959A (ja) * | 2003-10-28 | 2007-04-19 | アムゲン インコーポレイティッド | トリアゾール化合物およびそれに関連する使用法 |
EP1764360A4 (en) | 2004-07-02 | 2010-08-11 | Sankyo Co | UREA DERIVATIVE |
WO2006019020A1 (ja) * | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
AU2005280168A1 (en) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylimidazoles as TGF-beta inhibitors |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
WO2006051662A1 (ja) * | 2004-11-09 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | チアゾール誘導体 |
KR100848205B1 (ko) * | 2005-06-20 | 2008-07-24 | 주식회사 동부하이텍 | 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물 |
ATE529405T1 (de) * | 2006-03-31 | 2011-11-15 | Novartis Ag | (4-(4-ä6-(trifluoromethyl-pyridin-3-ylamino)-n- enthaltend-heteroarylü-phenyl)-cyclohexyl)- essigsäure-derivate und ihre pharmazeutische anwendungen |
ATE500251T1 (de) * | 2006-06-08 | 2011-03-15 | Astrazeneca Ab | Benzimidazole und ihre verwendung zur behandlung von diabetes |
TW200815437A (en) | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
-
2008
- 2008-04-30 US US12/112,635 patent/US8242139B2/en not_active Expired - Fee Related
- 2008-04-30 RU RU2009144113/04A patent/RU2497816C2/ru not_active IP Right Cessation
- 2008-04-30 EP EP08795827A patent/EP2142521A1/en not_active Withdrawn
- 2008-04-30 AU AU2008245461A patent/AU2008245461B2/en not_active Ceased
- 2008-04-30 BR BRPI0810719A patent/BRPI0810719A8/pt not_active IP Right Cessation
- 2008-04-30 KR KR1020097024972A patent/KR20100017508A/ko not_active Application Discontinuation
- 2008-04-30 MX MX2009011754A patent/MX2009011754A/es active IP Right Grant
- 2008-04-30 CN CN200880022907A patent/CN101743234A/zh active Pending
- 2008-04-30 EP EP12154263A patent/EP2452937A1/en not_active Ceased
- 2008-04-30 CA CA002685529A patent/CA2685529A1/en not_active Abandoned
- 2008-04-30 WO PCT/US2008/061951 patent/WO2008134693A1/en active Application Filing
- 2008-04-30 JP JP2010506586A patent/JP2010526781A/ja active Pending
- 2008-04-30 NZ NZ580660A patent/NZ580660A/en not_active IP Right Cessation
- 2008-04-30 CN CN201310546161.6A patent/CN103641823A/zh active Pending
-
2009
- 2009-10-25 IL IL201753A patent/IL201753A0/en unknown
- 2009-10-29 ZA ZA2009/07613A patent/ZA200907613B/en unknown
-
2012
- 2012-07-16 US US13/549,651 patent/US8901152B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2497816C2 (ru) | 2013-11-10 |
CN101743234A (zh) | 2010-06-16 |
ZA200907613B (en) | 2013-04-24 |
US8901152B2 (en) | 2014-12-02 |
NZ580660A (en) | 2012-02-24 |
KR20100017508A (ko) | 2010-02-16 |
US20080312282A1 (en) | 2008-12-18 |
AU2008245461A1 (en) | 2008-11-06 |
AU2008245461B2 (en) | 2012-12-06 |
IL201753A0 (en) | 2010-06-16 |
CN103641823A (zh) | 2014-03-19 |
CA2685529A1 (en) | 2008-11-06 |
BRPI0810719A2 (pt) | 2014-10-21 |
US20120277223A1 (en) | 2012-11-01 |
US8242139B2 (en) | 2012-08-14 |
BRPI0810719A8 (pt) | 2016-03-08 |
EP2452937A1 (en) | 2012-05-16 |
RU2009144113A (ru) | 2011-06-10 |
JP2010526781A (ja) | 2010-08-05 |
EP2142521A1 (en) | 2010-01-13 |
WO2008134693A1 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009011754A (es) | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. | |
MX2009011753A (es) | Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1. | |
WO2007137103A3 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
WO2007137107A3 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
HK1133596A1 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
WO2008049123A8 (en) | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
WO2007098507A3 (en) | Compositions and methods for inhibition of the jak pathway | |
TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
JO2870B1 (en) | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes | |
TW200744586A (en) | Therapeutic compounds | |
WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2008054698A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
MX2020009397A (es) | Composiciones y metodos para inhibicion de la via jak. | |
WO2010124121A8 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
DE502005010342D1 (en) | Substituierte cyclohexylessigsäure-derivate | |
MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
WO2010039518A3 (en) | Tricyclic carbamate jak inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |